Sly Syndrome: Clinical Trials

4 trials for Sly Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 active not recruiting, 1 terminated. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Completed 2, Active not recruiting 1, Terminated 1

Follow Sly Syndrome: new trials by email Literature Review of Sly Syndrome trials Research Report on Sly Syndrome

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age
UX003 - Sly Syndrome, MPS VII
Phase 2CompletedUltragenyx Pharmaceutical Inc82015-07-212019-10-30
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
Stem Cell Transplantation, IMD Preparative Regimen, Osteopetrosis Only Preparative Regimen - Mucopolysaccharidosis Disorders, Hurler Syndrome
Phase 2Active not recruitingMasonic Cancer Center, University of Minnesota1492014-07-102026-11-03
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
Campath-1H, Cyclophosphamide, Busulfan - Mucopolysaccharidosis, Hurler Syndrome
Phase 2CompletedMasonic Cancer Center, University of Minnesota462009-12-012018-02-05
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
Stem Cell Transplantation, Cyclophosphamide, Campath-1H - Hurler's Syndrome, Maroteaux-Lamy Syndrome
Phase 2TerminatedMasonic Cancer Center, University of Minnesota182008-03-012017-12-28

Narrower conditions

Mucopolysaccharidosis VII (4)  ·  Aspartylglucosaminuria (3)  ·  Fucosidosis (3)  ·  Leukodystrophy, Globoid Cell (3)  ·  Leukodystrophy, Metachromatic (3)  ·  Mucopolysaccharidosis I (3)  ·  Mucopolysaccharidosis VI (3)  ·  Peroxisomal Disorders (3)  ·  Sphingolipidoses (3)  ·  alpha-Mannosidosis (3)  ·  Mucopolysaccharidoses (2)  ·  Mucopolysaccharidosis II (2)  ·  Adrenoleukodystrophy (1)  ·  Alpha-Methylacyl-CoA Racemase Deficiency (1)  ·  Hereditary Diffuse Leukoencephalopathy with Spheroids (1)

Broader conditions

Carbohydrate Metabolism, Inborn Errors (4)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4)  ·  Connective Tissue Diseases (4)  ·  Genetic Diseases, Inborn (4)  ·  Mucinoses (4)  ·  Nutritional and Metabolic Diseases (4)  ·  Skin and Connective Tissue Diseases (4)  ·  Brain Diseases (3)  ·  Brain Diseases, Metabolic (3)  ·  Brain Diseases, Metabolic, Inborn (3)  ·  Central Nervous System Diseases (3)  ·  Demyelinating Diseases (3)  ·  Hereditary Central Nervous System Demyelinating Diseases (3)  ·  Leukoencephalopathies (3)  ·  Lipid Metabolism Disorders (3)

Interventions

Stem Cell Transplantation (3)  ·  Alemtuzumab (2)  ·  Busulfan (2)  ·  Cyclophosphamide (2)  ·  Bone Marrow Transplantation (1)  ·  Cyclosporine (1)  ·  Mycophenolic Acid (1)  ·  Regimen B (1)  ·  vestronidase alfa (1)

Sponsors

Masonic Cancer Center, University of Minnesota (3)  ·  Ultragenyx Pharmaceutical Inc (1)

Countries

United States (4)  ·  Portugal (1)  ·  Spain (1)

Top investigators

Paul Orchard, MD (2)  ·  Paul Orchard, M.D. (1)

Results publications

PMID 21586746, PMID 30467742, PMID 35331634, PMID 37415957

NIH funding

2015 (1)